Health Condition 1: B079- Viral wart, unspecified
Conditions
Interventions
Intervention1: intralesional injection of Inj Vitamin D3(6,00,000IU
15 mg/ml): Patients will receive intralesional injection of upto 0.5 mL of Inj Vitamin D3(6,00,000IU
15 mg/ml)into a wart each session after injection of IL lignocaine with 31 G insulin syringe.Amount of injection on each wart will depend on the size of each wart. The intralesional injection will be
Sponsors
Teerthankar Mahaveer Medical College and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed patients of warts attending the Department of Dermatology, Venereology & Leprosy(both out-patient and in-patient)of Teerthankar Mahaveer Medical College,Moradabad(UP) 2. Age from 12 years to 70 years of both sexes 3.Patients giving informed and willing consent
Exclusion criteria
Exclusion criteria: 1.Patients under any systemic or topical treatment of warts for the last 4 weeks 2.PatientswithapasthistoryofanallergicresponsetoMMRoranyothervaccineorVitaminD3. 3.Patientswithcurrentacutefebrileillness,anybacterialinfection,immunocompromisedandonimmunosuppressants 4.Pregnantandlactatingfemales 5.Patientswithhistoryofkeloid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • To determine the efficacy of IL MMR vaccine in the treatment of warts. • To determine the efficacy of IL vitamin D3 in the treatment of warts. • To compare the efficacy of IL MMR vaccine and IL Vitamin D3 during follow up using dermoscopy. To identify various dermoscopic features of warts before and after immunotherapy.Timepoint: 3,6,9,12 weeks,1,2,3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the side effects of IL MMR vaccine and IL Vitamin D3 in treatment of warts.Timepoint: 3,6,9,12 weeks,1,2,3 months | — |
Countries
India
Contacts
Public ContactDr Dilip Meena
Teerthankar Mahaveer Medical College and Research Centre
Outcome results
None listed